Pathogenesis and management of iron toxicity in thalassemia

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 1-9

  Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

erythropoiesis; iron; thalassemia major

Indexed keywords

CARDIOLIPIN; CYSTEINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DNA; FERRITIN; FREE RADICAL; HYDROGEN PEROXIDE; IRON; PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

AGRANULOCYTOSIS; ARTHRALGIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CELL COMPARTMENTALIZATION; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENDOCRINE DISEASE; ERYTHROPOIESIS; EYE TOXICITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART MUSCLE; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; IRON TRANSPORT; LIFE EXPECTANCY; LIPID MEMBRANE; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; LYSOSOME; MICROSOME; MITOCHONDRION; NEUTROPENIA; OTOTOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PEROXISOME; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIDEROSIS; SURVIVAL; THALASSEMIA MAJOR;

EID: 77955915545     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05544.x     Document Type: Conference Paper

References (40)

1. Finch, C.A., K. Deubelbeiss, J.D. Cook, et al. 1970. Ferrokinetics in man. Medicine (Baltimore) 49: 17-53.
2. Tanno, T., N.V. Bhanu, P.A. Oneal, et al. 2007. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Med. 13: 1096-1101.
3. Hershko, C., G. Graham, G. Bates & E. Rachmilewitz. 1978. Non-specific serum iron in thalassaemia; an abnormal serum fraction of potential toxicity. Br. J. Haematol. 40: 255-263.
4. Evans, R.W., R. Rafique, A. Zarea, et al. 2008.Nature of nontransferrin- bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13: 57-74.
5. Oudit, G.Y., H. Sun, M.G. Trivieri, et al. 2003. l-Type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. NatureMed. 9: 1187-1194.
6. Halliwell, B. & J.M. Gutteridge. 1992. Biologically relevant metal ion-dependent hydroxyl radical generation. An update. FEBS Lett. 307: 108-112.
7. Cadenas, E. 1989. Biochemistry of oxygen toxicity. Annu. Rev. Biochem. 58: 79-110.
8. Houglum, K., M. Filip, J.L. Witztum & M. Choikier. 1990. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J. Clin. Invest. 86: 1991-1998.
9. Pitkainen, S. & B.H. Robinson. 1996. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J. Clin. Invest. 98: 345-351.
10. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 2004. Survival and complications in patients with thalassemiamajor treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
11. Hershko, C. & D. Weatherall. 1988. Iron chelating therapy. CRC Crit. Rev. Clin. Lab. Sci. 26: 303-345.
12. Cabantchik, Z.I., W. Breuer, G. Zanninelli & P. Cianciulli. 2005. LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18: 277-287.
13. Porter, J.B., R.D. Abeysinghe, L.Marshall, et al. 1996. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88: 705-713.
14. Porter, J.B., S. Singh, K.P. Hoyes, et al. 1994. Lessons from preclinical and clinical studies with 1,2-diethyl-3- hydroxypyridin-4-one, CP94 and related compounds. Adv. Exp. Med. Biol. 356: 361-370.
15. Glickstein, H., R.B. El, M. Shvartsman & Z.I. Cabantchik. 2005. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106: 3242-3250.
16. Cooper, C.E., G.R. Lynagh, K.P. Hoyes, et al. 1996. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 271: 20291-20299.
17. Gabutti, V. & C. Borgna-Pignatti. 1994. Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's Clin. Haematol. 7: 919-940.
18. Davis, B.A., C. O'Sullivan, P.H. Jarritt, et al. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269.
19. Modell, B., M. Khan & M. Darlison, 2000. Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2052.
20. Hershko, C., G. Link, A. Pinson, et al. 1991. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood 77: 2049-2053.
21. Piga, A., C. Gaglioti, E. Fogliacco, et al. 2003. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 88: 489-496.
22. Borgna-Pignatti, C., M.D. Cappellini, P. De Stefano, et al. 2006. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107: 3733-3737.
23. Pennell, D.J., V. Berdoukas, M. Karagiorga, et al. 2006. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107: 3738-3744.
24. Nisbet-Brown, E., N.F. Olivieri, P.J. Giardina, et al. 2003. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361: 1597-1602.
25. Cappellini, M.D., A. Cohen, A. Piga, et al. 2006. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107: 3455-3462.
26. Glickstein, H, R.B. El, G. Link, et al. 2006. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108: 3195-3203.
27. Hershko, C., A.M. Konijn, H.P. Nick, et al. 2001. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97: 1115-1122.
28. Wood, J.C., M. Otto-Duessel, M.Aguilar, et al. 2005. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112: 535-543.
29. Pennell, D.J., J.B. Porter, M.D. Cappellini, et al. 2010. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 115: 2364-2371.
30. Cappellini, M.D., J.D. Porter, A. El-Beshlawy, et al. 2010. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 95: 557-566.
31. Hoffbrand, A.V., A. Cohen & C. Hershko. 2003. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102: 17-24.
32. Hershko, C., G. Link, A. Konijn & Z.I. Cabantchik. 2005. Objectives and mechanism of iron chelation therapy. Ann. N. Y. Acad. Sci. 1054: 124-135.
33. Wonke, B., C. Wright & A.V. Hoffbrand. 1998. Combined therapywith deferiprone and desferrioxamine.Br. J.Haematol. 103: 361-364.
34. Tanner, M.A., R. Galanello, C. Dessi, et al. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115: 1876-1884.
35. Origa, R., P. Bina, A. Agus, et al. 2005. Combined therapy with deferiprone and desferrioxamine in thalassemiamajor. Haematologica 90: 1309-1314.
36. Telfer, P., P.G. Coen, S. Christou, et al. 2006. Survival of medically treated thalassemia patients inCyprus. Trends and risk factors over the period 1980-2004. Haematologica 91: 1187-1192.
37. Maggio, A., A. Vitrano, M. Capra, et al. 2009. Long-termsequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br. J. Haematol. 145: 245-254.
38. Taher, A., A. El-Beshlawy, M.S. Elalfy, et al. 2009. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur. J. Haematol. 82: 458-465.
39. Daar, S., A. Pathare, H. Nick, et al. 2009. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur. J. Haematol. 82: 454-457.
40. Zanninelli, G., W. Breuer & Z.I. Cabantchik. 2009. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br. J. Haematol. 147: 744-751.